Fulvestrant

Generic Name: Fulvestrant

Brand Names: Faslodex, Fulvestrant Mylan

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₇F_₅O_₃S

CAS Number: 129453-61-8

Unique Ingredient Identifier: 22X328QOC4

Background: Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer

Indication: For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions: Advanced Breast Cancer, Advanced or Metastatic Breast Cancer

Clinical Trials

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Phase 3

Active, not recruiting

Conditions: Neoplasm Metastasis
Breast Neoplasm

Interventions: Drug: Abemaciclib
Drug: Fulvestrant
Drug: Placebo

First Posted Date: 2021-12-27

Last Posted Date: 2025-04-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 368

Registration Number: NCT05169567

Locations: 🇨🇳
Taipei Tzu Chi General Hospital, New Taipei City, Taiwan
🇩🇰
Regionshospitalet Gødstrup, Herning, Midtjylland, Denmark
🇭🇺
Bacs-Kiskun Megyei Korhaz, Kecskemét, Bács-Kiskun, Hungary

and more 130 locations

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Ribociclib
Drug: Letrozole
Drug: Anastrozole
Drug: Goserelin
Drug: Tamoxifen
Drug: Fulvestrant

First Posted Date: 2021-12-17

Last Posted Date: 2025-05-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT05161195

Locations: 🇺🇸
University Hospitals of Cleveland Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸
Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States
🇺🇸
Millennium Research Clin Develop, Houston, Texas, United States

and more 14 locations

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometroid Endometrial Cancer

Interventions: Drug: Alpelisib Pill
Drug: Fulvestrant injection

First Posted Date: 2021-12-13

Last Posted Date: 2024-12-19

Lead Sponsor: GOG Foundation

Target Recruit Count: 51

Registration Number: NCT05154487

Locations: 🇺🇸
AdventHealth Gynecologic Oncology, Orlando, Florida, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Tampa General Hospital, Tampa, Florida, United States

and more 8 locations

Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-

Conditions: Breast Neoplasm Female

First Posted Date: 2021-12-01

Last Posted Date: 2021-12-01

Lead Sponsor: Dr. Reddy's Laboratories SAS

Target Recruit Count: 40

Registration Number: NCT05140655

Locations: 🇨🇴
SOHEC, Valledupar, Cesar, Colombia

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Phase 2

Recruiting

Conditions: Ovarian Cancer
Serous Ovarian Cancer

Interventions: Drug: Regorafenib
Drug: Fulvestrant

First Posted Date: 2021-11-09

Last Posted Date: 2024-12-11

Lead Sponsor: Sarah K. Lynam MD

Target Recruit Count: 31

Registration Number: NCT05113368

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer
HER2-negative Breast Cancer
ER Positive Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant
Drug: Zotatifin
Drug: Tamoxifen

First Posted Date: 2021-11-01

Last Posted Date: 2024-07-11

Lead Sponsor: Stanford University

Target Recruit Count: 19

Registration Number: NCT05101564

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer
Breast Cancer Stage IV
Metastatic Breast Cancer

Interventions: Dietary Supplement: Low Carbohydrate Diet
Dietary Supplement: Ketogenic Diet
Drug: Alpelisib
Drug: Fulvestrant
Drug: Canagliflozin

First Posted Date: 2021-10-22

Last Posted Date: 2025-05-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT05090358

Locations: 🇺🇸
Ohio State University (Data Collection & Data Analysis), Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 6 locations